Anticoagulation is unnecessary after biological aortic valve replacement

Area of Science:

• Cardiology
• Cardiac Surgery
• Vascular Surgery

Background:

• Postoperative anticoagulation strategies after biological aortic valve replacement (AVR) are debated for preventing ischemic stroke.
• Current evidence is insufficient to definitively establish the benefit of early anticoagulation.

Purpose of the Study:

• To assess the efficacy of early anticoagulation with heparin and warfarin in preventing early postoperative ischemic stroke after biological AVR.
• To determine if early anticoagulation confers any significant advantage in this patient population.

Main Methods:

• Retrospective analysis of patients undergoing biological AVR between 1987 and 1996.
• Comparison of two groups: Group A (n=109) received heparin followed by warfarin for 3 months; Group B (n=76) received no anticoagulation.
• Follow-up included cerebral ischemic events, bleeding, repeat operations, hospital stay, and survival rates.

Main Results:

• No statistically significant differences in cerebral ischemic events were observed between the anticoagulation and no-anticoagulation groups at any time point.
• Bleeding complications, mean hospital stay, and rates of repeat AVR were similar between the two groups.
• Kaplan-Meier survival analysis showed no significant difference in long-term survival between groups (P = 0.60).

Conclusions:

• Early anticoagulation following biological AVR does not offer an advantage in preventing early cerebral ischemic events.
• Withholding early anticoagulation did not result in disadvantages regarding bleeding, hospital stay, or long-term valve function and survival.
• The study concludes that early anticoagulation is unnecessary after biological AVR.